Pharma Marketletter

View more issues:

Articles in April, 2003 issue of Pharma Marketletter

• Stock Commentary - Europe.
• Revenues up at Merck & Co on key drug sales, profits hit by increased spending.
• DTB finds no evidence of autism with MMR.
• US states "failing to monitor effects of Rx prior authorization under Medicaid".
• Israel's health reforms: a "basket" case, a road map and a heavyweight.
• Stock Commentary - Europe.
• Firms overcharged $6.1M for 11 drugs: HHS.
• US Court OKs Michigan preferred drug lists.
• Regeneron dives as statement on Phase III obesity trial alarms investors.
• Array BioPharma lowers forecasts.
• Tokyo pharma stocks - week to April 7.
• S-P, Novartis link up on asthma product.
• Biogen raises forecast, shares up on news.
• OSI Pharma shares gyrate as investors react to Tarceva update.
• Shock French move as Minister slashes reimbursement on 617 drugs.
• S African Rx price panel plan is extremist and against free trade, says NAPM.
• Cytos beats forecasts with 2002 results.
• Merck & Co's Emend cleared by FDA for nausea in cancer chemotherapy.
• UK NICE to view statins, antipsychotics, etc.
• ProEthic transdermal ketoprofen deal.
• Lilly "spying" prompts Hungarian price move.
• EU Parliament votes to support stem cell research ban.
• AstraZeneca rations drug supplies to Canadian pharmacies.
• UPDATE: Allos Therapeutics' brain cancer trial misses primary endpoint.
• Biogen's 1st-qtr profit down, underlying growth edges up on Avonex sales.
• Stock Commentary - Europe.
• Stock Commentary - Tokyo.
• Licensing still vital to SkyePharma in 2003.
• SangStat boosted by new data on inflammatory bowel disease treatment.
• War, terror and terrorism overshadow normally sanguine FDLI meeting.
• Stock Commentary - New York.
• Profits flat at Novartis despite sales growth.
• Novartis' Certican tops azathioprine.
• Takeda forecasts 315B yen profit in 2004.
• Stock Commentary - New York.
• California directs HMOs over switched drugs.
• Merck KGaA lifted by Erbitux trial review.
• ImClone to restate earnings for 2001/02.
• As FDA moves to efficient risk management, pharma "must make similar reforms".
• US HHS warns of FDA workload fears; should 10-month NDA goal be extended?
• Stock Commentary - Tokyo.
• Xenova: progress with therapeutic vaccines.
• Red tape delays AIDS grant to South Africa.
• Pfizer boosted by disposals in 1st-qtr, double-digit sales and EPS growth.
• Europe goes on-line for health info, but still prefers traditional sources.
• Stock Commentary - New York.
• Update - AstraZeneca 's Crestor: ACC studies.
• Cyprotex' losses soar after 1st trading period.
• Stock Commentary - Europe.
• Profits and sales up at J&J in first quarter on higher prescription turnover.
• XOMA and Genentech expand Raptiva collaboration.
• Evans aborts OGS bid, Celltech set to triumph.
• Antidepressant sales boost Forest in 4th qtr.
• Update: Regeneron dives on Phase III obesity trial.
• Threats to innovation could see drug R&D fall into a "death spiral," says Eli Lilly CEO.
• Genzyme fined L6.8M over market abuse regarding Cerezyme in the UK.
• Pharmacia gets US approval for acromegaly treatment Somavert.
• China tightens controls on drugs and biologicals, approves food/drug admin.
• Forest's memantine Ph III Alzheimer's trial.
• The future of orphan drugs: FDLI meeting.
• GSK faces challenging times, says Wood Mackenzie.
• Allos Therapeutics' brain cancer trial misses primary endpoint.
• Chugai chief reviews pipeline, business prospects post Roche alliance.
• Underlying growth beats forecasts at Lilly.
• AstraZeneca says Lipitor users benefit from switch to Crestor.
• US Congress urged over web pharmacy.
• Fujisawa adopts fresh management strategy.
• Schwarz lifts forecasts on strong generic sales.
• China pharma ind to become competitive.
• Gedeon Richter sees product mix improve in 2002.
• Amgen outperforms in 1st qtr, raises forecast.
• Exanta study tops expectations.
• Roche CEO reiterates 2003 forecasts.
• State of play in human embryonic stem cell research: Euro Commission report.
• McClellan says FDA will encourage generics but slams makers over approval delays.
• Stock Commentary - Tokyo.
• Evans aborts OGS bid, Celltech set to triumph.
• Pfizer deal finally cleared by FTC and trading to commence; Hassan's future?
• Renagel sales boost Genzyme in 1st-qtr.
• Losses up at TKT but Replagal sales recover.

• 1
• 2